Chris GarabedianChairman and CEO
Chris Garabedian is a biotechnology executive that most recently served as the President and Chief Executive Officer of Sarepta Therapeutics from January 2011-March 2015 and as a member of Sarepta's board of directors from June 2010-March 2015. He is currently involved in the formation and co-founding of several early-stage biopharma companies.
Mr. Garabedian served as Vice President of Corporate Strategy for Celgene from 2007 to December 2010 where he was responsible for strategic planning, M&A, portfolio review and other strategic initiatives. Prior to Celgene, Mr. Garabedian worked at Gilead Sciences, Inc., from 1997 to 2005 where he served in a number of global leadership roles, including as Vice President of Corporate Development, Vice President of Marketing, and Vice President of Medical Affairs. While at Gilead Sciences, Mr. Garabedian's responsibilities ranged from managing corporate development initiatives, including portfolio review and strategic planning, M&A/business development, and leading four global product launches. Mr. Garabedian also held various commercial development positions at COR Therapeutics, Inc. from 1998 to 1999 and at Abbott Laboratories from 1994 to 1997. He started his biopharmaceutical career as a consultant with Migliara/Kaplan Associates from 1991 to 1994.
Mr. Garabedian is a frequent speaker across a variety of topics at industry conferences. He also serves as a member of faculty of the GLG Institute, is a Senior Advisor with the Boston Consulting Group, and is on the Board of Advisors for the Keck Graduate Institute.